Loading…
← CockpitCompetitor Analysis › 008930.KS Hanmi ScienceOpen in the cockpit ↗

Hanmi Science008930.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Medical Distributors

Holding company atop Hanmi Pharmaceutical group, also running early-stage biotech and health-related ventures.

Momentum leader 97
Mkt cap
$2.58B
US dollars, full cap
Free float
15%
of shares outstanding
$/day
$9.22M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-1.8 pp
WACC 5.6%
Hurdle
+16 pp
Req g minus delivered
Close · KRW₩52,400
1D-3.7%
1W-6.1%
1M+19.0%
3M+18.3%
6M+48.2%
YTD+45.7%
1Y+34.0%
ATR %7.4%
52w lowhigh17.9% off high

What Hanmi Science does

Holding company atop Hanmi Pharmaceutical group, also running early-stage biotech and health-related ventures.

A pure holding company: its income is dividends and brand fees from subsidiaries, so it gets the group's profits only after they are paid out. Hanmi Pharmaceutical is the main operating subsidiary.

Products and services

  • Hanmi Pharmaceutical stake
  • Early-stage biotech ventures

Where it sits in the supply chain

  • Pharma holding company
  • R&D-focused pharma group
  • Group holding structure

What could go right

  • Hanmi Pharmaceutical pipeline/licensing progress

What could go wrong

  • Holding-company discount
  • Subsidiary R&D/clinical risk

Moat: none. Pure holding company; value depends on operating subsidiary Hanmi Pharmaceutical.

Headquarters: Seoul, South Korea · Employees: 489

Named competitors

Hanmi Science at a glance

Size Hanmi Science (008930.KS) is a South Korea Health Care company (Medical Distributors) with a market value of $2.58B, the 113th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩52,400 on 18 Nov 2026.

Performance Over six months the shares gained 48.2%, against +7.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 6.2% over the last twelve months (peer median +5.5%); the operating margin is 4.2% (peer median 3.0%).

Valuation It trades at 2.5× enterprise value to sales against a peer median of 0.5× (most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.8 points below its cost of capital (5.6% WACC).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026008930.KS 150Peer median 107
Six months, rebased to 100: Hanmi Science against the median of its 20 peers (local-currency closes).

Hanmi Science financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩1.43T₩1.36T₩1.28T₩1.25T₩1.05T
Revenue growth—+6%+3%+19%—
Gross profit₩293B₩272B₩233B₩227B₩102B
EBITDA₩68.6B₩66.4B₩47.7B₩65.7B₩33.6B
Net income₩134B₩118B₩59.4B₩115B₩69.2B
Free cash flow₩21.1B₩28.7B₩73.2B₩28.2B₩2.32B
Capital expenditure₩18.3B₩21.0B₩11.7B₩8.77B₩8.44B
Total debt₩184B₩215B₩227B₩222B₩202B

Quarterly statements and history in the cockpit →

Hanmi Science competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%-10%0%+10%+20%ASKER278499873349AMP7459600998RDC3360GALEDKSH6005877476DOCM3015846007131099603368ARJO-B008930.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Hanmi Science is the large dot.

Fundamentals: revenue growth against valuation

0%+5%+10%0×1×2×ASKER278499873349AMP7459600998RDC3360GALEDKSH6005877476DOCM6007131099603368ARJO-B008930.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hanmi Science is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%ASKER27849987AMP60099881293360GALEDKSH301584008930.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hanmi Science is the large dot.

Hanmi Science competitors and peer comparison

Head to head with its named competitors (008930.KS vs 128940.KS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Hanmi Science 008930.KS$2.58B+48%+6%4%2.5×26.0%
HanmiPharm 128940.KS$3.95B-2%+14%16%3.3×4.7%

How Hanmi Science compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hanmi Science against its 20 peers (data as of 18 Nov 2026)
Measure008930.KSPeer medianRank in peer set
1-month return+19.0%+1.8%2nd highest of 21
6-month return+48.2%+7.6%3rd highest of 21
Distance from 52-week high-17.9%-14.3%9th lowest of 21
Revenue growth (TTM)+6.2%+5.5%10th highest of 21
Operating margin4.2%3.0%8th highest of 21
EV / Sales2.5×0.5×most expensive of 21
Growth the price implies (Req g, 7 yrs)26.0%-3.7%most demanding of 17
Growth delivered (Del g)+9.6%+4.6%4th highest of 17
Hurdle (Req g minus delivered)+16.4 pp-8.9 ppmost demanding of 17
ROIC minus cost of capital-1.8 pp+1.7 pp3rd lowest of 21
Net debt / EBITDA1.2×0.5×7th most indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Hanmi Science 008930.KSSouth Korea$2.58B+48%+6%4%2.5×26.0%+9.6%
Asker Healthcare ASKER.STSweden$2.69B-14%+12%7%1.8×4.7%+12.7%
Alfresa 2784.TJapan$2.81B-3%+4%1%0.1×-8.4%+3.5%
Suzuken 9987.TJapan$2.36B+8%+5%1%0.1×-10.4%+3.2%
COSMOS Pharmaceutical 3349.TJapan$3.21B+2%+9%4%0.5×n/an/a
Amplifon AMP.MIItaly$3.39B+8%0%10%1.7×6.8%+9.8%
MEDIPAL 7459.TJapan$3.70B+15%+4%1%0.1×-7.2%+3.5%
Jointown Pharmaceutical 600998.SSChina$3.99B+7%+9%2%0.4×0.2%+7.8%
Toho 8129.TJapan$1.64B-5%+4%1%0.1×-4.6%+5.1%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%0.5×n/an/a
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%0.2×-14.5%+7.6%
Galenica GALE.SWSwitzerland$5.31B+8%+6%5%1.3×7.0%+3.5%
DKSH DKSH.SWSwitzerland$5.99B+24%-1%3%0.5×-1.2%+0.6%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%0.6×-6.9%+1.2%
AS ONE 7476.TJapan$1.10B+25%+10%12%1.3×0.0%+6.3%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%1.0×n/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%0.5×-2.7%+17.9%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%0.3×n/an/a
Sinopharm 1099.HKHong Kong$6.74B0%+3%3%0.3×-7.3%+4.0%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%0.4×-9.7%+6.0%
Arjo ARJO-B.STSweden$974M+42%0%8%1.3×-1.0%+3.9%

Questions

Who are Hanmi Science's main competitors?
Named competitors: HanmiPharm (128940.KS). The cockpit's measured peer set (industry) also includes Asker Healthcare (ASKER.ST), Alfresa (2784.T), Suzuken (9987.T), COSMOS Pharmaceutical (3349.T), Amplifon (AMP.MI), MEDIPAL (7459.T).
Is Hanmi Science expensive compared with its peers?
On ev / sales it trades at 2.5× against a peer median of 0.5×, most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Hanmi Science stock performed?
Over six months to 18 Nov 2026 the shares returned +48.2% against +7.6% for the median peer; over one year +34.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.